Dr. Rumey Ishizawar’s Research Finds Rheumatoid Arthritis (RA) Patients May Safely Receive Immune Checkpoint Inhibitors (ICIs) for Cancer Treatment
The study evaluated whether pre-existing RA was associated with a higher mortality and risk for immune-related adverse events with ICI use.